Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Zampini M, Riva E, Lanino L, Sauta E, Dos Reis R, Ejarque R, Maggioni G, Termanini A, Merlotti A, Campagna A, Dall’Olio L, Kulasekararaj A, Calvi M, Di Vito C, Bonometti A, Rahal D, Croci G, Boveri E, Gianelli U, Ponzoni M, Caselli R, Albertazzi S, Todisco G, Ubezio M, Crisafulli L, Frigo A, Lugli E, Mosca E, Acha P, Ghisletti S, Nicassio F, Santoro A, Diez-Campelo M, Solé F, Ades L, Platzbecker U, Santini V, Fenaux P, Haferlach T, Sallman D, Garcia-Manero G, Mavilio D, Remondini D, Castellani G, D'Amico S, Zeidan A, Komrokji R, Kordasti S, Ficara F, Della Porta M, Consortium C, Russo A, Travaglino E, Delleani M, Asti G, Ventura D, Tentori C, Buizza A, Brindisi M, Pinocchio N, Pesce F. Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. Journal Of Clinical Oncology 2025, 43: 2069-2083. PMID: 40315418, PMCID: PMC12169866, DOI: 10.1200/jco-24-02394.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeP53 dysfunctionPhenotype of immune cellsClassification of myeloid neoplasmsIdentified high-risk patientsImpaired antigen presentationOptimal timing of therapeutic interventionsAbnormal p53 proteinHigh-risk patientsSubsets of patientsBone marrow progenitorsTiming of therapeutic interventionDesign of clinical trialsRecognition of patientsTumor protein 53Variant allele frequencyNF-kB pathwayInnovative immunotherapyMyeloid neoplasmsDismal outcomeMarrow progenitorsImmune dysregulationBiallelic inactivationImmune cellsPoor prognosisBroxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases
Tang H, Zou X, Chen P, Wang Y, Gao S, Wang T, Xu Y, Ji S. Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases. International Immunopharmacology 2025, 156: 114687. PMID: 40253767, DOI: 10.1016/j.intimp.2025.114687.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisNLR family pyrin domain-containing 3Inflammasome activationInflammatory diseasesASC speck formationInflammasome-associated diseasesNEK7-NLRP3 interactionDamage signalingNF-kB pathwayHost defensePyrin domain-containing 3Speck formationAIM2 inflammasome activationActivation of NLRP3 inflammasomeFamily pyrin domain-containing 3Autoimmune encephalomyelitisMurine modelInterleukin-1bIL-1BInhibiting inflammasome activationNLRP3 inflammasome inhibitorAntimicrobial drugsNF-kBProteinTherapeutic agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply